文献速递浆细胞疾病造血干细胞移植与细胞治疗

伊沙佐米与安慰剂作为多发性骨髓瘤移植后维持治疗:缓解加深与无进展生存期改善相关

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
PubMed 文献 · Leukemia · 2020-04-23

TOURMALINE-MM3研究显示,自体干细胞移植后口服蛋白酶体抑制剂伊沙佐米维持治疗较安慰剂显著改善无进展生存期(PFS)且安全性良好。入组时达非常好的部分缓解或部分缓解(VGPR/PR)者中,伊沙佐米组139/302(46%)vs 安慰剂组60/187(32%)出现缓解加深(相对风险1.41,P=0.004),中位至最佳确认加深缓解时间19.9 vs 30.8个月(24个月率54.2% vs 41.4%;HR 1.384;P=0.0342)。

要点

  • 伊沙佐米维持组缓解加深率46% vs 安慰剂组32%(相对风险1.41,P=0.004)。
  • 入组时VGPR/PR者中位PFS伊沙佐米组26.2个月 vs 安慰剂组18.5个月(HR 0.636,P<0.001)。
  • 合并分析中,有 vs 无缓解加深者中位PFS未达到 vs 15.9个月(HR 0.245,P<0.001)。

核心结论

  • 伊沙佐米维持治疗较安慰剂显著提高缓解加深率,且缓解加深与PFS延长相关。

研究设计与样本

  • TOURMALINE-MM3研究:自体干细胞移植后多发性骨髓瘤患者随机接受口服蛋白酶体抑制剂伊沙佐米或安慰剂维持治疗。

主要发现

  • 入组时VGPR/PR者中,伊沙佐米组139/302(46%)vs 安慰剂组60/187(32%)出现缓解加深(相对风险1.41,P=0.004)。
  • 中位至最佳确认加深缓解时间伊沙佐米组19.9个月 vs 安慰剂组30.8个月(24个月率54.2% vs 41.4%;HR 1.384;P=0.0342)。
  • 入组时VGPR/PR者中位PFS伊沙佐米组26.2个月 vs 安慰剂组18.5个月(HR 0.636,P<0.001)。
  • 合并分析中,有 vs 无缓解加深者中位PFS未达到 vs 15.9个月(HR 0.245,P<0.001)。
  • 有缓解加深者中24个月PFS率伊沙佐米组77.4% vs 安慰剂组68.3%(HR 0.831;P=0.466);无缓解加深者中位PFS伊沙佐米组17.9个月 vs 安慰剂组14.1个月(HR 0.741;P=0.028)。

关键数值与推荐

  • 缓解加深定义及评估标准未在摘要中报告。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Goldschmidt H, Dimopoulos MA, Rajkumar SV, et al. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. 2020. PMID: 32327729. doi:10.1038/s41375-020-0819-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。